Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions

被引：15
|
作者：
Ambati, Srikanth R. [1 ]
Slotkin, Emily K. [1 ]
Chow-Maneval, Edna [2 ]
Basu, Ellen M. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
[2] Ignyta, San Diego, CA USA
来源：
JCO PRECISION ONCOLOGY | 2018年 / 2卷
基金：
美国国家卫生研究院;
关键词：
LYMPHOMA KINASE ALK; CLINICAL-RESPONSE; PAN-TRK; INHIBITOR; SARCOMA;
D O I：
10.1200/PO.18.00095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1 / 6
页数：6
相关论文
共 50 条
  • [1] PRECLINICAL AND CLINICAL EFFICACY OF ENTRECTINIB IN PRIMARY AND METASTATIC BRAIN TUMORS HARBORING NTRK, ROS1, OR ALK GENE FUSIONS
    Rangaraju, S.
    Farago, A.
    Heym, K. M.
    Ahn, M.
    Drilon, A.
    Potts, S.
    Hornby, Z.
    Multani, P.
    Li, G.
    NEURO-ONCOLOGY, 2017, 19 : 106 - 106
  • [2] Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Rearrangements and Rare Novel RET Gene Fusions
    Antonescu, Cristina
    Suurmeijer, Albert
    Zhang, Lei
    Sung, Yun-Shao
    Jungbluth, Achim
    Travis, William
    Al-Ahmadie, Hikmat
    Fletcher, Christopher
    Alaggio, Rita
    MODERN PATHOLOGY, 2015, 28 : 14A - 14A
  • [3] Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Rearrangements and Rare Novel RET Gene Fusions
    Antonescu, Cristina
    Suurmeijer, Albert
    Zhang, Lei
    Sung, Yun-Shao
    Jungbluth, Achim
    Travis, William
    Al-Ahmadie, Hikmat
    Fletcher, Christopher
    Alaggio, Rita
    LABORATORY INVESTIGATION, 2015, 95 : 14A - 14A
  • [4] Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET Rearrangement
    Antonescu, Cristina R.
    Suurmeijer, Albert J. H.
    Zhang, Lei
    Sung, Yun-Shao
    Jungbluth, Achim A.
    Travis, William D.
    Al-Ahmadie, Hikmat
    Fletcher, Christopher D. M.
    Alaggio, Rita
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (07) : 957 - 967
  • [5] PEDIATRIC PHASE 1/1B STUDY OF ENTRECTINIB IN PATIENTS WITH PRIMARY BRAIN TUMORS, NEUROBLASTOMA, AND NTRK, ROS1, OR ALK FUSIONS
    Rangaraju, Sunitha
    Li, Gang
    Christiansen, Jason
    Hornby, Zachary
    Multani, Pratik
    Esquibel, Vanessa
    Maneval, Edna Chow
    NEURO-ONCOLOGY, 2017, 19 : 53 - 53
  • [6] Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions
    Dai, Yinghuan
    Liu, Ping
    He, Wenlong
    Yang, Lizhen
    Ni, Yang
    Ma, Xuejiao
    Du, Furong
    Song, Chao
    Liu, Yang
    Sun, Yi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Expression of ROS1 Predicts ROS1 Gene Rearrangement in Inflammatory Myofibroblastic Tumors
    Hornick, J. L.
    Sholl, L. M.
    Lovly, C. M.
    LABORATORY INVESTIGATION, 2014, 94 : 18A - 18A
  • [8] Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors
    Hornick, Jason L.
    Sholl, Lynette M.
    Dal Cin, Paola
    Childress, Merrida A.
    Lovly, Christine M.
    MODERN PATHOLOGY, 2015, 28 (05) : 732 - 739
  • [9] Expression of ROS1 Predicts ROS1 Gene Rearrangement in Inflammatory Myofibroblastic Tumors
    Hornick, J. L.
    Sholl, L. M.
    Lovly, C. M.
    MODERN PATHOLOGY, 2014, 27 : 18A - 18A
  • [10] ALK and ROS1 Expression in Inflammatory Myofibroblastic Tumor
    Yamamoto, Hidetaka
    Taguchi, Kenichi
    Yoshida, Akihiko
    Kohashi, Kenichi
    Oda, Yoshinao
    LABORATORY INVESTIGATION, 2015, 95 : 29A - 29A
12345